Semaglutide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Semaglutide (Semaglutide (GLP-1 receptor agonist)) is a GLP-1 receptor agonist incretin mimetic. Synthetic GLP-1 analog developed by Novo Nordisk with amino acid modifications for extended half-life. It is researched for weight loss (16-22.5%), glycemic control, cardiovascular event reduction, appetite suppression. Common dosages range from 0.25-2.4 mg weekly (injection) or 3-14 mg daily (oral) administered once weekly (injection) or daily (oral).
What Is Semaglutide?
Semaglutide (Semaglutide (GLP-1 receptor agonist)) is a GLP-1 receptor agonist incretin mimetic. Synthetic GLP-1 analog developed by Novo Nordisk with amino acid modifications for extended half-life. Also known as Ozempic, Wegovy, Rybelsus, it has been studied for its potential effects on weight loss (16-22.5%), glycemic control, cardiovascular event reduction, appetite suppression.
Only GLP-1 agonist with both injectable and oral formulations, approved across three distinct indications (diabetes, obesity, kidney disease) — the most versatile weight loss peptide on the market. In the research community, Semaglutide has gained attention for its distinctive profile.
How Does Semaglutide Work?
Activates GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion and inhibit glucagon release. Crosses the blood-brain barrier to activate hypothalamic GLP-1 receptors, reducing hunger signaling, increasing satiety, and modulating energy expenditure through CNS appetite pathways.
This multi-pathway activity helps explain why Semaglutide shows potential across several different applications.
What Does the Research Say About Semaglutide?
STEP trials: 16-22.5% weight loss at 2.4 mg vs 3.1% placebo at 68 weeks. Multiple cardiovascular outcome trials. Approved for diabetes (2017), weight management (2021), and kidney disease (2025). 15,000+ clinical trial subjects.
Researchers should consult the latest peer-reviewed literature for the most current findings.
What Is the Recommended Semaglutide Dosage?
Standard Semaglutide dosing: 0.25-2.4 mg weekly (injection) or 3-14 mg daily (oral), administered once weekly (injection) or daily (oral) via subcutaneous injection or oral.
Half-life: 7 days. Cycle length: ongoing, titrated over 4-5 weeks.
Use our peptide dosing calculator for exact reconstitution ratios.
Calculate Your Semaglutide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Semaglutide.
Open Calculator →What Are the Side Effects of Semaglutide?
Nausea, vomiting, diarrhea (20-40% incidence, decreasing over 4-8 weeks). Thyroid C-cell tumor risk in rodents (human relevance unclear). Rare pancreatitis and diabetic retinopathy worsening.
Semaglutide is fda-approved for type 2 diabetes (ozempic), weight management (wegovy), and chronic kidney disease. prescription medication.
Can You Stack Semaglutide With Other Peptides?
Dual pathway activation possible with GIP agonists (tirzepatide). Complements SGLT2 inhibitors for enhanced glycemic control.
What Is the Bottom Line on Semaglutide?
Semaglutide is a GLP-1 receptor agonist incretin mimetic researched for weight loss (16-22.5%), glycemic control, cardiovascular event reduction, appetite suppression. Standard protocols use 0.25-2.4 mg weekly (injection) or 3-14 mg daily (oral) once weekly (injection) or daily (oral) for ongoing, titrated over 4-5 weeks.
Source from COA-tested vendors. Read our beginner's guide for more, or use the dosing calculator to plan your protocol.
Complete Guide
Semaglutide : Benefits, Dosage, Side Effects & Research
Related Reading
- Semaglutide Dosage Guide
- Semaglutide Benefits
- Semaglutide Side Effects
- Semaglutide Stacking Guide
- Semaglutide Cycle Guide
- Semaglutide Research
Research-Grade Sourcing
If you're going to research Semaglutide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Semaglutide?
Semaglutide (Semaglutide (GLP-1 receptor agonist)) is a GLP-1 receptor agonist incretin mimetic. Synthetic GLP-1 analog developed by Novo Nordisk with amino acid modifications for extended half-life. It is researched for weight loss (16-22.5%), glycemic control, cardiovascular event reduction, appetite suppression.
What is the recommended Semaglutide dosage?
Common dosages: 0.25-2.4 mg weekly (injection) or 3-14 mg daily (oral) administered once weekly (injection) or daily (oral) via subcutaneous injection or oral. Cycle length: ongoing, titrated over 4-5 weeks. Half-life: 7 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Semaglutide?
Nausea, vomiting, diarrhea (20-40% incidence, decreasing over 4-8 weeks). Thyroid C-cell tumor risk in rodents (human relevance unclear). Rare pancreatitis and diabetic retinopathy worsening.
Is Semaglutide safe?
Semaglutide has shown a preliminary safety profile in research. FDA-approved for type 2 diabetes (Ozempic), weight management (Wegovy), and chronic kidney disease. Prescription medication. All research should follow appropriate safety protocols.